![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessGlycemic status, non-traditional risk and left ventricular structure and function in the Jackson Heart Study
Left ventricular structure and function abnormalities may be an early marker of cardiomyopathy among African Americans with diabetes (DM) even in the absence of coronary artery disease (CAD), arrhythmia, valvu...
-
Article
Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications
Multiple newer medications benefit patients with heart failure with reduced ejection fraction (HFrEF). While these therapies benefit the broad population with HFrEF, the efficacy and safety of these therapies ...
-
Article
Targeting Natriuretic Peptide Levels in Heart Failure with Therapy: Does “X” Really Mark the Spot?
Explore controversial biomarker-guided management of patients with heart failure (HF) with reduced ejection fraction.
-
Article
Global Variations in Patient Populations and Outcomes in Heart Failure Clinical Trials
Heart failure is a global pandemic and there has been a growing effort to enroll patients from different geographical regions in randomized controlled trials. In this review, we examined regional variation in ...
-
Article
Comorbidities in Heart Failure: Are There Gender Differences?
Compared to men, women with heart failure (HF) are often older, smoke less, and have more preserved ejection fraction (EF) and hypertensive HF rather than HF of ischemic etiology. Gender-stratified outcomes on...
-
Article
Global Perspectives in Hospitalized Heart Failure: Regional and Ethnic Variation in Patient Characteristics, Management, and Outcomes
Heart failure (HF) is a public health problem of global proportions afflicting more than 25 million patients worldwide. Despite stable or declining per capita hospitalization rates in the USA and several Europ...